Xenophontos E, Konstantinou I, Kountourakis P, et al. - Researchers used retrospective data from patients’ medical charts to determine disease-free survival (DFS) and overall survival (OS) for consecutive patients suffering from stage I-III colon cancer over a 10-year span. The study sample comprised 556 patients with a median age at diagnosis of 67 (range 18-88), most of them being male (60%). Chemotherapy was used to treat just over half of stage II patients. Stage III cases were given CapeOx (48%); FOLFOX (28%); capecitabine (12%); 5-fluorouracil (4%); and 8% underwent no treatment. At 5 years, DFS was estimated to be 90%, 85%, and 69%, and cancer-specific OS was noted to be 94%, 93%, and 81%, for stage I, stage II, and stage III, respectively. At 10 years, there were still favorable outcomes (stage I 94%; stage II 84%; and stage III 70%). The results generated were highly consistent with those published in the international literature, despite a fragmented healthcare system with multiple referring surgeons from the private and public sectors, and this can be because of optimal multidisciplinary management as well as follow-up care.